Received Jun 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 3 | — | — |
No side effects or symptoms have been reported. No Additional AE/No PQC; HCP called to report a patient did not received their GARDASIL 9 doses according to the recommended dosing schedule. Caller states the patient recieved their first dose in 2020 (exact date unknown0, their second dose in 2021 (exact date unknown) and; This spontaneous report was received from a/an Pharmacist and refers to a(n) 22-year-old female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 2020, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), formulation: injection, 0.5 mL (lot #, expiration date, route of administration and anatomical location were not provided) for prophylaxis. On 2021, the patient was vaccinated with the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), formulation: injection, 0.5 mL (lot #, expiration date, route of administration and anatomical location were not provided) for prophylaxis. On 2025, the patient was vaccinated with the third dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), formulation: injection, 0.5 mL (lot #, expiration date, route of administration and anatomical location were not provided) for prophylaxis (inappropriate schedule of product administration). No side effects or symptoms have been reported (no adverse event).